Solid Biosciences Inc.: insider trading
254 trades by 33 directors, officers and 10% owners since 2018, from their SEC Form 4 and 5 filings.
Bought, 12 months
$0
0 purchases by 0 insiders
Sold, 12 months
$2.7 M
28 sales by 7 insiders
Bought, 3 months
$0
0 purchases
Sold, 3 months
$25 K
1 sale
Insider buying and selling by month
Open-market purchases and sales by value, last three years.
Insiders (33)
Each insider's latest direct holding and their open-market trades of the last 12 months, most recent first.
| Insider | Shares owned directly | Bought, 12 m | Sold, 12 m | Latest trade |
|---|---|---|---|---|
| Gabriel BrooksChief Medical Officer | 97,241 | — | $288 K | |
| Ian F. SmithDirector | 141,585 | — | — | |
| Alexander CumboPresident and CEO, Director | 235,405 | — | $984 K | |
| David T. HowtonChief Operating Officer | 105,077 | — | $434 K | |
| Ilan GanotDirector | 99,297 | — | $69 K | |
| Jessie HanrahanChief Regulatory Officer | 74,318 | — | $297 K | |
| Kevin TanCFO & Treasurer | 99,422 | — | $330 K | |
| Paul HerzichChief Technology Officer | 72,638 | — | $274 K | |
| Clare KahnDirector | 2,960 | — | — | |
| BCLS SB Investco, LP10% owner | — | — | — | |
| Joseph EdelmanDirector, 10% owner | — | — | — | |
| Robert Atchinson10% owner | — | — | — | |
| Adam KoppelDirector, 10% owner | — | — | — | |
| Perceptive Xontogeny Venture Fund, LPDirector, 10% owner | — | — | — | |
| RA Capital Nexus Fund, L.P.Director, 10% owner | — | — | — | |
| Jennifer MarloweCSO | 6,998 | — | — | |
| Carl Ashley MorrisChief Scientific Officer | 19,760 | — | — | |
| Ra Capital Management, L.P.Director, 10% owner | — | — | — | |
| Schneider Joel Solomon ZevChief Operating Officer | 236,270 | — | — | |
| RA Capital Healthcare Fund LPDirector, 10% owner | — | — | — | |
| Peter KolchinskyDirector, 10% owner | — | — | — | |
| Jennifer Lynn ZiolkowskiCFO, Treasurer & Asst. Secy | 335,636 | — | — | |
| Matthew Bennett ArnoldDirector | 3.93 M | — | — | |
| Rajeev M. ShahDirector, 10% owner | — | — | — | |
| Lynette HerschaChief Legal Officer | 160,859 | — | — | |
| Martin I. FreedDirector | 53,763 | — | — | |
| Perceptive Advisors LLCDirector, 10% owner | — | — | — | |
| Sukumar NagendranDirector | 34,258 | — | — | |
| Juan Andrey ZarurDirector | 691,105 | — | — | |
| Boxer Capital, LLC10% owner | 3.47 M | — | — | |
| Pedro Alvaro AmorrortuChief Operating Officer | 153,746 | — | — | |
| Jorge Armando QuirozChief Medical Officer | 228,092 | — | — | |
| Gilad David Hayeem10% owner | 1.95 M | — | — |
Trades#
| Traded | Insider | Trade | Shares | Price | Value | Owned after | Filing |
|---|---|---|---|---|---|---|---|
| filed | Clare KahnDirector | Buy | +1,860 | $5.340 | $10 K | 2,960 | Form 4 |
| filed | Joseph EdelmanDirector, 10% owner | Buyindirect | +5.00 M | $4.030 | $20.1 M | 11.83 M | Form 4 |
| filed | BCLS SB Investco, LP10% owner | Buyindirect | +1.00 M | $4.030 | $4.0 M | 5.03 M | Form 4 |
| filed | Robert Atchinson10% owner | Buyindirect | +252,545 | $7.560 | $1.9 M | 4.25 M | Form 4 |
| filed | Clare KahnDirector | Buy | +1,100 | $7.670 | $8 K | 1,100 | Form 4 |
| filed | RA Capital Nexus Fund, L.P.Director, 10% owner | Buyindirect | +904,160 | $5.530 | $5.0 M | 4.19 M | Form 4 |
| filed | Perceptive Xontogeny Venture Fund, LPDirector, 10% owner | Buyindirect | +3.41 M | $5.530 | $18.9 M | 6.83 M | Form 4 |
| filed | Joseph EdelmanDirector, 10% owner | Buyindirect | +2.61 M | $5.750 | $15.0 M | 13.41 M | Form 4 |
| filed | Peter KolchinskyDirector, 10% owner | Buyindirect | +2.21 M | $5.750 | $12.7 M | 10.92 M | Form 4 |
| filed | Perceptive Advisors LLCDirector, 10% owner | Buyindirect | +2.82 M | $4.650 | $13.1 M | 6.75 M | Form 4 |
| filed | Adam KoppelDirector | Buyindirect | +300,000 | $16.00 | $4.8 M | 1.99 M | Form 4 |
| filed | Perceptive Advisors LLCDirector, 10% owner | Buyindirect | +1.00 M | $16.00 | $16.0 M | 3.91 M | Form 4 |
| filed | Rajeev M. ShahDirector | Buyindirect | +1.00 M | $16.00 | — | 2.69 M | Form 4 |
| filed | Perceptive Advisors LLCDirector, 10% owner | Buyindirect | +20,000 | $27.33 | $547 K | 3.93 M | Form 4 |
Source: SEC Forms 4 and 5. A trade under a 10b5-1 plan was scheduled in advance. For information only; not investment advice